Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

nts received G1 doses of 30ug/kg/day, while E1 doses started at 0.3ug/kg/day for most patients with some patients escalating to E1 doses of 0.5ug/kg/day or reducing to 0.2ug/kg/day. In the trial, 30 type 2 diabetes patients on oral anti-diabetic agents (metformin with/without TZD) were enrolled. These patients continued on their oral anti-diabetic medication for the duration of the trial. Upon entry into the trial, the patients' HbA1c levels ranged between 6.8% and 10.9%, with a mean HbA1c level of 8.1%. Transition reported interim unblinded data from this study in a press release dated March 5th, 2007.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include regenerative therapies E1-I.N.T.(TM) and GLP1-I.N.T.(TM) for the treatment of diabetes and AZD-103/ELND-005 for the treatment of Alzheimer's disease. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition's shares are listed on the Toronto Stock Exchange under the symbol "TTH". For additional information about the company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including funding and conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:8/27/2015)... August 27, 2015 According to a new ... Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage ... 2020", published by MarketsandMarkets, the Medical Lifting Sling Market is poised ... in 2015, at a CAGR of 11.4 % from 2015 to ... ma rket data T ables and 65 ...
(Date:8/27/2015)... --  Women Grow , the fastest-growing professional networking organization for ... Cannabis World Congress & Business Exposition (CWCBExpo) in ... educational sessions. CWCBExpo in LA will take place September 16-18, ... Center in Los Angeles, CA , and ... the marijuana industry. The Women Grow tracks at ...
(Date:8/27/2015)... Aug. 27, 2015  A mere one in seven ... Allen Hamilton . A new white paper ... are impeding and disrupting manufacturers, success. The ... Improve Value In Product Development Processes provides insight ... and how it affects the product development process resulting ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2
... no stent thrombosis or MACE,after one year, ... 2007,/PRNewswire-FirstCall/ -- Boston Scientific Corporation today,welcomed the ... FIRST, II,and III Clinical Trials, reaffirming prior ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System and XIENCE(TM) V ...
... of Choroidal,Neovascularization (CNV) in an AMD Model, SAN ... ,the category leader in therapeutic agents against bioactive ... of human age-related macular degeneration (AMD). , The ... the,Association of Research in Vision and Ophthalmology (ARVO) ...
Cached Medicine Technology:SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 2SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... a low cost. Personalized with practice contact information and logos, Calendars stand alone ... can also incorporate Calendars into seasonal mailings, thank you and welcome communications, and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout ... go deep sea diving. The act of recreational diving exposes the body ... reasons, it is vital that all recreational and professional divers undergo regular comprehensive ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... of the top 5 millionaire dating sites . According to the listings, ... the second best in this category. , A spokesperson of Top5MillionaireDatingSites.com ...
(Date:8/28/2015)... ... , ... Inc. magazine today ranked PREVENT Life Safety No. 3660 ... private companies. The list was unveiled online at Inc.com and is the most competitive ... years, PREVENT ranks higher on the list than any other company in their industry. ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... tailor therapy regimen to individuals, experts say , , TUESDAY, ... affect the way children respond to treatment for lymphoblastic ... children suffering from this type of blood and bone ... to treatment. Now researchers think they know why. , ...
... radiation indicates need for earlier screening, study notes, , , ... female childhood cancer survivors under the age of 40 ... are not following the recommended advice to get screening ... The recommendation suggests starting screening mammograms at age 25, ...
... Ill., Jan. 27 EngagementHealth, LLC., an innovator ... launch of its comprehensive disease prevention and health ... RBNF ). Rurban Financial is a leading ... services, and bank data and item processing, headquartered ...
... point-of-use and central pharmacy automation solutionsMOUNTAIN VIEW, Calif., Jan. ... a leading provider of system solutions to acute healthcare ... by Emory Healthcare for Omnicell point-of-use and central pharmacy ... (NASDAQ: OMCL ) is a leading provider ...
... 27, 2009 Environmental Tobacco Smoke (ETS) commonly called ... account for complications during pregnancy and birth. It is ... than do whites from smoking and ETS exposure. In ... the American Journal of Preventive Medicine , researchers ...
... Jan. 27 Trust for America,s Health (TFAH) applauds ... funding to improve the health of Americans while stimulating ... "This funding is desperately needed to revitalize and ... be putting more Americans to work in programs that ...
Cached Medicine News:Health News:In Kids, Genes May Affect Leukemia Treatment 2Health News:In Kids, Genes May Affect Leukemia Treatment 3Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 3Health News:EngagementHealth(R) Launches Comprehensive Wellness Programs With Rurban Financial Corp. (Nasdaq - RBNF) 2Health News:Avoiding secondhand smoke during pregnancy 2Health News:Trust for America's Health Applauds Public Health Funding in Senate Stimulus Bill as Down Payment for Containing Health Care Costs 2Health News:Trust for America's Health Applauds Public Health Funding in Senate Stimulus Bill as Down Payment for Containing Health Care Costs 3
... and Response catheters comprise the world's ... for electrophysiology procedures. Their advanced catheter ... superior torque response with a soft, ... and French sizes, Supreme and Response ...
... Jude Medical's line of guiding introducers ... RAMP, and 2 piece steerable, all ... catheters when the varying curves and ... physician technique. St. Jude Medical guiding ...
Novus 3000 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
... provide outstanding insertion performance, with ... high kink resistance and minimal ... sheath cannula provides optimal strength ... an extra strong dilator to ...
Medicine Products: